Base de dados : MEDLINE
Pesquisa : D04.210.500.745.745.654.829.025 [Categoria DeCS]
Referências encontradas : 64 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 64 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26718719
[Au] Autor:Chen Y; Hong WS; Wang Q; Chen SX
[Ad] Endereço:State Key Laboratory of Marine Environmental Science, Xiamen University, Xiamen 361102, China; College of Ocean and Earth Sciences, Xiamen University, Xiamen 361102, China.
[Ti] Título:Cloning and pattern of gsdf mRNA during gonadal development in the protogynous Epinephelus akaara.
[So] Source:Anim Reprod Sci;165:46-55, 2016 Feb.
[Is] ISSN:1873-2232
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Gonadal soma-derived factor (gsdf) is a teleost- and gonad-specific growth factor involved in early germ cell development. The red spotted grouper, Epinephelus akaara, as a protogynous hermaphrodite, provides a novel model for understanding the mechanisms of sex determination and differentiation in teleosts. In the present study, a 2307-bp long gsdf gene was cloned from E. akaara and there was further analysis of its tissue distribution and gonadal patterns of gene expression during the female phase and sex change developmental stages. The cellular localization of gsdf at the late transitional developmental stage was also analyzed. In addition, the concentrations of serum sex steroid hormones (E2, 11-KT and DHP) were determined. The gsdf transcripts were exclusively localized in the gonad. During the female phase at an early developmental stage, when the ovotestis contained mainly oogonia and primary growth oocytes, the gsdf mRNA was relatively more abundant. The relative abundance of gsdf decreased, however, and the lesser amount was sustained with the advancement of oocyte development. During the transitional phase, the relative abundance of gsdf mRNA increased slightly at the early developmental stage and there were further increases in relative abundance in the late developmental stage, and the gsdf transcripts were observed in the Sertoli cells surrounding early developing spermatogonia. Among the sex steroids, 11-KT concentrations were positively correlated with amount of gsdf mRNA during sex change. These results suggest that gsdf could have roles in regulating pre-meiotic germ cell proliferation and be involved in sex change in E. akaara.
[Mh] Termos MeSH primário: Clonagem Molecular
Peixes/fisiologia
Regulação da Expressão Gênica no Desenvolvimento/fisiologia
Gônadas/crescimento & desenvolvimento
Organismos Hermafroditas/metabolismo
Peptídeos e Proteínas de Sinalização Intercelular/metabolismo
[Mh] Termos MeSH secundário: Algestona/sangue
Sequência de Aminoácidos
Animais
Estradiol/sangue
Feminino
Gônadas/metabolismo
Organismos Hermafroditas/genética
Peptídeos e Proteínas de Sinalização Intercelular/genética
Dados de Sequência Molecular
Filogenia
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
Testosterona/análogos & derivados
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Intercellular Signaling Peptides and Proteins); 0 (RNA, Messenger); 3JEB53B3WT (Algestone); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); KF38W1A85U (11-ketotestosterone)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160101
[St] Status:MEDLINE


  2 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:18843662
[Au] Autor:Gallo MF; Grimes DA; Lopez LM; Schulz KF; d'Arcangues C
[Ad] Endereço:Division of Reproductive Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Mail Stop K-34, Atlanta, Georgia 30341-3724, USA.
[Ti] Título:Combination injectable contraceptives for contraception.
[So] Source:Cochrane Database Syst Rev;(4):CD004568, 2008 Oct 08.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Combination injectable contraceptives provide a highly effective, reversible method of preventing pregnancy, and they do not require daily administration or use at the time of coitus. Although they are used in many countries, their acceptability could be limited by method characteristics, such as the need to obtain a monthly injection or bleeding pattern changes. OBJECTIVES: To assess the contraceptive efficacy, bleeding patterns, discontinuation, user preferences, and side effects of combination injectable contraceptives. SEARCH STRATEGY: We searched computerized databases for randomized controlled trials of combination injectable contraceptives. SELECTION CRITERIA: Randomized controlled trials were eligible if they compared a combination injectable with any other contraceptive method (e.g., a second combination injectable contraceptive, progestin-only injectable contraceptive, other hormonal contraceptive or barrier method) or placebo. We limited the review to currently marketed combination injectable contraceptives. DATA COLLECTION AND ANALYSIS: One author evaluated all titles and abstracts from the literature searches to determine their eligibility. Two authors independently extracted data from the eligible trials. Data on contraceptive efficacy, bleeding patterns, continuation, and side effects were entered and analyzed with RevMan. MAIN RESULTS: Combination injectable contraceptives include depot medroxyprogesterone acetate (DMPA) 25 mg plus estradiol cypionate (E(2)C) 5 mg, as well as norethisterone enanthate (NET-EN) 50 mg plus estradiol valerate (E(2)V) 5 mg. These contraceptives resulted in lower rates of early study discontinuation due to amenorrhea or other bleeding problems than progestin-only contraceptives. However, rates were higher for overall discontinuation and discontinuation due to other medical reasons. Acceptability results favored the combination injectable in one study and the progestin-only in another.Studies comparing two combination injectable contraceptives found that NET-EN 50 mg plus E(2)V 5 mg resulted in less overall discontinuation and less discontinuation due to amenorrhea or prolonged bleeding than DMPA 25 mg plus E(2)C 5 mg. However, these differences were not detected in all trials. The NET-EN plus E(2)V group also had more regular bleeding and fewer prolonged bleeding reference periods than the DMPA plus E(2)C group. The groups did not differ in their amenorrhea rates. AUTHORS' CONCLUSIONS: While discontinuation rates can be viewed as a measure of method acceptability, the findings should be interpreted with caution since discontinuation depends on many factors. Future research should be directed toward interventions to improve the acceptability of combination injectable contraceptives, such as providing injections in settings more convenient than clinics, methods for women to administer their own injections, and counseling about possible bleeding pattern changes.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Anticoncepcionais Femininos/administração & dosagem
[Mh] Termos MeSH secundário: Algestona/administração & dosagem
Anticoncepcionais Femininos/efeitos adversos
Combinação de Medicamentos
Estradiol/administração & dosagem
Feminino
Seres Humanos
Injeções
Adesão à Medicação
Medroxiprogesterona/administração & dosagem
Acetato de Megestrol/administração & dosagem
Noretindrona/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Combinations); 3JEB53B3WT (Algestone); 4TI98Z838E (Estradiol); HSU1C9YRES (Medroxyprogesterone); T18F433X4S (Norethindrone); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:0901
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:081010
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD004568.pub3


  3 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:16034938
[Au] Autor:Gallo MF; Grimes DA; Schulz KF; d'Arcangues C; Lopez LM
[Ad] Endereço:IPAS, 300 Market Street, suite 200, Chapel Hill, North Carolina 27516, USA. gallom@ipas.org
[Ti] Título:Combination injectable contraceptives for contraception.
[So] Source:Cochrane Database Syst Rev;(3):CD004568, 2005 Jul 20.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Combination injectable contraceptives provide a highly effective, reversible method of preventing pregnancy, and they do not require daily administration or use at the time of coitus. Although they are used in many countries, their acceptability could be limited by method characteristics, such as the need to obtain a monthly injection or bleeding pattern changes. OBJECTIVES: To assess the contraceptive efficacy, bleeding patterns, discontinuation, user preferences, and side effects of combination injectable contraceptives. SEARCH STRATEGY: We searched computerized databases for randomized controlled trials of combination injectable contraceptives. SELECTION CRITERIA: Randomized controlled trials reported in any language were eligible if they compared a combination injectable with any other contraceptive method (e.g., a second combination injectable contraceptive, progestin-only injectable contraceptive, other hormonal contraceptive or barrier method) or placebo. We limited the review to currently marketed combination injectable contraceptives. DATA COLLECTION AND ANALYSIS: The primary reviewer evaluated all titles and abstracts from the literature searches to determine their eligibility. Two reviewers independently extracted data from the eligible trials. Data on contraceptive efficacy, bleeding patterns, continuation, and side effects were entered and analyzed with RevMan 4.2. MAIN RESULTS: Combination injectable contraceptives include depot medroxyprogesterone acetate (DMPA) 25 mg plus estradiol cypionate (E(2)C) 5 mg, as well as norethisterone enanthate (NET-EN) 50 mg plus estradiol valerate (E(2)V) 5 mg. These combination injectable contraceptives resulted in lower rates of early study discontinuation due to amenorrhea or other bleeding problems, but had higher rates of discontinuation due to other reasons than the progestin-only comparison contraceptives. Studies comparing two combination injectable contraceptives found that NET-EN 50 mg plus E(2)V 5 mg resulted in less overall early discontinuation and less discontinuation due to amenorrhea or prolonged bleeding than DMPA 25 mg plus E(2)C 5 mg. However, these differences were not detected in all trials making this comparison. The NET-EN plus E(2)V group also had more cyclical (regular) bleeding and fewer prolonged bleeding reference periods than the DMPA plus E(2)C group. The groups did not differ in their amenorrhea rates. AUTHORS' CONCLUSIONS: While discontinuation rates can be viewed as a measure of method acceptability, the findings should be interpreted with caution since discontinuation rates are dependent on many other factors. Future research should be directed toward interventions to improve the acceptability of combination injectable contraceptives, such as providing injections in settings more convenient than clinical sites, methods for women to administer their own injections, and counseling about possible bleeding pattern changes.
[Mh] Termos MeSH primário: Anticoncepção/métodos
Anticoncepcionais Femininos/administração & dosagem
[Mh] Termos MeSH secundário: Algestona/administração & dosagem
Combinação de Medicamentos
Estradiol/administração & dosagem
Feminino
Seres Humanos
Injeções
Medroxiprogesterona/administração & dosagem
Acetato de Megestrol/administração & dosagem
Noretindrona/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 0 (Drug Combinations); 3JEB53B3WT (Algestone); 4TI98Z838E (Estradiol); HSU1C9YRES (Medroxyprogesterone); T18F433X4S (Norethindrone); TJ2M0FR8ES (Megestrol Acetate)
[Em] Mês de entrada:0511
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050722
[St] Status:MEDLINE


  4 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10659704
[Au] Autor:Berrie JR; Williams RA; Smith KE
[Ad] Endereço:Department of Biochemistry, Queen Mary and Westfield College, London, UK.
[Ti] Título:Microbial transformations of steroids-XI. Progesterone transformation by Streptomyces roseochromogenes-purification and characterisation of the 16alpha-hydroxylase system.
[So] Source:J Steroid Biochem Mol Biol;71(3-4):153-65, 1999 Dec 15.
[Is] ISSN:0960-0760
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Streptomyces roseochromogenes, NCIB 10984, contains a cytochrome P450 which, in conjunction with two indigenous electron transfer proteins, roseoredoxin and roseoredoxin reductase, hydroxylates exogenous progesterone firstly to 16alpha-hydroxyprogesterone and thereafter in a second phase bioconversion to 2beta,16alpha-dihydroxyprogesterone. The progesterone 16alpha-hydroxylase P450 and the two electron transfer proteins have been purified to homogeneity. A reconstituted incubation containing these three purified proteins and NADH, the natural electron donor, produced identical hydroxy-progesterone metabolites as in intact cells. Peroxy and hydroperoxy compounds act in a shortened form of the cycle known as the 'peroxide shunt' by replacing the natural pathway requirement for the electron donor NADH, the electron transfer proteins and molecular O2, the terminal electron acceptor. In an NaIO4 supported incubation, the initial rate of progesterone hydroxylation was marginally higher (1.62 mmol progesterone/mmol P-450/h) than in the reconstituted natural incubation (1.18 mmol progesterone/mmol P-450/h) but the product yield was significantly lower, 0.45 mol hydroxyprogesterone produced/mol P-450 compared to 6.0 mol hydroxyprogesterone produced/mol P-450. These yield data show that in the reconstituted natural pathway, progesterone 16alpha-hydroxylase P450 supports multiple rounds of hydroxylation in contrast to a likely single oxygenation by a minority of P450s in the peroxide shunt pathway.
[Mh] Termos MeSH primário: Hidrocarboneto de Aril Hidroxilases
Sistema Enzimático do Citocromo P-450/isolamento & purificação
Sistema Enzimático do Citocromo P-450/metabolismo
Progesterona/metabolismo
Esteroide Hidroxilases/isolamento & purificação
Esteroide Hidroxilases/metabolismo
Streptomyces/metabolismo
[Mh] Termos MeSH secundário: Algestona/metabolismo
Proteínas de Bactérias/isolamento & purificação
Proteínas de Bactérias/metabolismo
Transporte de Elétrons
Ferredoxinas/isolamento & purificação
Ferredoxinas/metabolismo
Cinética
Espectroscopia de Ressonância Magnética
NAD/metabolismo
Oxirredutases/isolamento & purificação
Oxirredutases/metabolismo
Esteroide 16-alfa-Hidroxilase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Ferredoxins); 0 (roseoredoxin); 0U46U6E8UK (NAD); 3JEB53B3WT (Algestone); 4G7DS2Q64Y (Progesterone); 9035-51-2 (Cytochrome P-450 Enzyme System); EC 1.- (Oxidoreductases); EC 1.14.- (Steroid Hydroxylases); EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases); EC 1.14.14.1 (Steroid 16-alpha-Hydroxylase); EC 1.18.- (roseoredoxin reductase)
[Em] Mês de entrada:0002
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000205
[St] Status:MEDLINE


  5 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9918380
[Au] Autor:Nieuwenhuizen AG; Schuiling GA; Hilbrands LG; Bisschop EM; Koiter TR
[Ad] Endereço:Department of Obstetrics & Gynaecology, University of Groningen, The Netherlands. a.g.nieuwenhuizen@med.rug.nl
[Ti] Título:Proliferation of pancreatic islet-cells in cyclic and pregnant rats after treatment with progesterone.
[So] Source:Horm Metab Res;30(11):649-55, 1998 Nov.
[Is] ISSN:0018-5043
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The effect of progesterone (P) on pancreatic islet-cell proliferation and function of cyclic and pregnant rats was investigated in vivo. Silastic tubes containing P were inserted s.c. in cyclic rats for 7 or 14 days and in pregnant rats from day 7 to 14, from day 14 to 21 or from day 7 to 21 of pregnancy. 5-Bromo-2-deoxyuridine (BrdU) was infused during the last 24h of the treatment; the proportion of dividing islet-cells was determined in pancreatic sections, which were immunostained for BrdU. Islet-cell function was determined by measuring glucose and insulin response to a standard intravenous glucose challenge. P treatment increased P and 20alpha-dihydroprogesterone (20alpha-OHP) levels in cyclic rats; in pregnant rats, only the plasma levels of 20alpha-OHP were elevated. Both 7 and 14 days of P treatment stimulated islet-cell proliferation in cyclic rats. In pregnant rats, P treatment increased islet-cell proliferation on day 14, but not on day 21 after either 7 or 14 days of P treatment. P did not affect plasma lactogenic activity in pregnant rats; plasma concentrations of prolactin were decreased after 14 days of P treatment in cyclic rats, but were not affected in pregnant rats. P treatment had no effect on glucose tolerance and glucose-stimulated insulin secretion in any of the groups. It was concluded that: 1. in vivo P stimulates islet-cell proliferation, but does not affect islet-cell function, 2. the stimulatory effects of P are indirect and possibly mediated by the P metabolite 20alpha-OHP and 3. at the end of gestation, stimulation of islet-cell proliferation is inhibited by some factor, which is not identical to P.
[Mh] Termos MeSH primário: Divisão Celular/efeitos dos fármacos
Ilhotas Pancreáticas/citologia
Progesterona/farmacologia
[Mh] Termos MeSH secundário: Algestona/sangue
Animais
Ingestão de Alimentos
Estro
Feminino
Idade Gestacional
Teste de Tolerância a Glucose
Insulina/secreção
Ilhotas Pancreáticas/secreção
Gravidez
Prolactina/sangue
Ratos
Ratos Wistar
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 3JEB53B3WT (Algestone); 4G7DS2Q64Y (Progesterone); 9002-62-4 (Prolactin)
[Em] Mês de entrada:9903
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990126
[St] Status:MEDLINE


  6 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9488670
[Au] Autor:Kelly-Hershkovitz E; Weizman R; Spanier I; Leschiner S; Lahav M; Weisinger G; Gavish M
[Ad] Endereço:Department of Pharmacology, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 31096 Haifa, Israel.
[Ti] Título:Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis.
[So] Source:J Biol Chem;273(10):5478-83, 1998 Mar 06.
[Is] ISSN:0021-9258
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The peripheral-type benzodiazepine receptor (PBR) is not only widely expressed throughout the body, but it is also genetically conserved from bacteria to humans. Many functions have been attributed to it, but its primary role remains a puzzle. In the current study, we stably transfected cultures of MA-10 Leydig cells with either control or 18-kDa PBR antisense knockout plasmids. The antisense knockout vector was driven by the human enkephalin promoter, which contains two cAMP response elements, such that cAMP treatment of transfected cells could superinduce 18-kDa PBR antisense RNA transcription and, hence, down-regulate endogenous 18-kDa PBR mRNA levels. Control and knockout MA-10 cell lines were then compared at the level of receptor binding, thymidine incorporation, and steroid biosynthesis. Eighteen-kilodalton PBR knockout reduced the maximal binding capacity of tritium-labeled PBR ligands, and the affinity of receptors to the ligands remained unaltered. Additionally, 24-h accumulation of progesterone was lower in the knockout cells. Exposure of the two cell types to 8-bromo-cAMP resulted in a robust increase in steroid production. However, a complex pattern of steroid accumulation was observed, in which further progestin metabolism was indicated. The later decline in accumulated progesterone as well as the synthesis of androstenedione were different in the two cell types. At the level of cell proliferation, reduction of 18-kDa PBR mRNA showed no effect. Thus, we conclude that the 18-kDa PBR may have a more important role in steroidogenesis than in proliferation in this Leydig cell line.
[Mh] Termos MeSH primário: DNA Antissenso/farmacologia
Antagonistas de Receptores de GABA-A
Células Intersticiais do Testículo/metabolismo
[Mh] Termos MeSH secundário: Algestona/metabolismo
Androstenodiona/metabolismo
Animais
Benzodiazepinonas/farmacologia
Divisão Celular/genética
Clonazepam/farmacologia
AMP Cíclico/análogos & derivados
AMP Cíclico/farmacologia
Isoquinolinas/metabolismo
Isoquinolinas/farmacologia
Masculino
Camundongos
Plasmídeos/genética
Progesterona/metabolismo
Ligação Proteica
RNA Mensageiro/metabolismo
Receptores de GABA-A/fisiologia
Transfecção/genética
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Benzodiazepinones); 0 (DNA, Antisense); 0 (GABA-A Receptor Antagonists); 0 (Isoquinolines); 0 (RNA, Messenger); 0 (Receptors, GABA-A); 2QW0IK1742 (4'-chlorodiazepam); 3JEB53B3WT (Algestone); 409J2J96VR (Androstenedione); 4G7DS2Q64Y (Progesterone); 5PE9FDE8GB (Clonazepam); E0399OZS9N (Cyclic AMP); YNF83VN1RL (PK 11195)
[Em] Mês de entrada:9804
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980416
[St] Status:MEDLINE


  7 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8935792
[Au] Autor:Foster WG; McMahon A; Rice DC
[Ad] Endereço:Environmental & Occupational Toxicology Division, Bureau of Chemical Hazards, Department of Health, Canada, Ottawa, Ontario.
[Ti] Título:Subclinical changes in luteal function in cynomolgus monkeys with moderate blood lead levels.
[So] Source:J Appl Toxicol;16(2):159-63, 1996 Mar-Apr.
[Is] ISSN:0260-437X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The objective of the present study was to investigate luteal function in cynomolgus monkeys (n = 32), aged 15-20 years with blood lead levels (BLLs) in the range of < 3.0 micrograms dl-1 (control, n = 20), 10-15 micrograms dl-1 (low, n = 7) and 25-30 micrograms dl-1 (moderate, n = 5). Sampling was performed daily beginning with day 10 of the menstrual cycle and concluding on the first day of the subsequent menstrual cycle. Circulating levels of oestradiol (E2), progesterone (P4) and 20 alpha-hydroxyprogesterone (20-OHP) were normalized to the day of the ovulatory E2 surge. The area under the concentration curve (AUC) for P4 was significantly lower in monkeys with moderate BLLs compared to the control group (P = 0.04). The number of days for which circulating levels of P4 were greater than 1.0 ng ml-1 were also significantly fewer (P = 0.03) in monkeys with moderate BLLs compared to controls. There was no statistical evidence of a lead effect on circulating levels of E2, 20-OHP or menstrual cycle characteristics. These data suggest that chronic lead exposure suppresses corpora luteal production of P4 in the monkey at circulating BLLs lower than previously reported and relevant to humans with occupational exposure to lead.
[Mh] Termos MeSH primário: Chumbo/toxicidade
Células Lúteas/efeitos dos fármacos
Compostos Organometálicos/toxicidade
Progesterona/sangue
[Mh] Termos MeSH secundário: Algestona/sangue
Animais
Relação Dose-Resposta a Droga
Estradiol/sangue
Feminino
Chumbo/sangue
Células Lúteas/metabolismo
Fase Luteal
Macaca fascicularis
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Organometallic Compounds); 2P299V784P (Lead); 3JEB53B3WT (Algestone); 4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol); RX077P88RY (lead acetate)
[Em] Mês de entrada:9701
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960301
[St] Status:MEDLINE


  8 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8812344
[Au] Autor:Yeoh CG; Schreck CB; Feist GW; Fitzpatrick MS
[Ad] Endereço:Oregon Cooperative Fishery Research Unit, Oregon State University, Corvallis 97331, USA.
[Ti] Título:Endogenous steroid metabolism is indicated by fluctuations of endogenous steroid and steroid glucuronide levels in early development of the steelhead trout (Oncorhynchus mykiss).
[So] Source:Gen Comp Endocrinol;103(1):107-14, 1996 Jul.
[Is] ISSN:0016-6480
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Concentrations of endogenous steroids and their glucuronide conjugates fluctuated during early development in steelhead trout Oncorhynchus mykiss. Whole body content of sex steroids and steroid glucuronides of both bisexual and gynogenetic (all female) steelhead trout were quantified by radioimmunoassay. Concentrations of 17beta-estradiol (E2) and cortisol increased 2-4 days before hatch. Two days after hatch, 11-ketotestosterone (11KT) increased in concentrations in both gynogenetic and bisexual populations, and 11KT glucuronide concentrations increased in the gynogenetic population. Testosterone (T) and E2 concentrations were at their lowest at 39 days postfertilization (dpf) for T and 39 and 61 dpf for E2. Changes in levels of steroid glucuronides were not consistently parallel to free steroids through time. T-, E2-, and 17alpha, 20beta dihydroxyprogesterone glucuronides declined slower than their free forms. Based on fluctuating concentrations of all steroid glucuronides, both populations of fish demonstrated an ability to form glucuronide conjugates of all steroids at the embryonic stage. The changes in levels of both free steroids and their glucuronides during early development of the trout indicate that steroid metabolism is active during development. This study also implicates steroid metabolism as an integral part of embryonic and postembryonic development.
[Mh] Termos MeSH primário: Oncorhynchus mykiss/crescimento & desenvolvimento
Oncorhynchus mykiss/metabolismo
Esteroides/metabolismo
[Mh] Termos MeSH secundário: Algestona/sangue
Animais
Estradiol/sangue
Feminino
Glucuronatos/metabolismo
Hidrocortisona/sangue
Concentração de Íons de Hidrogênio
Masculino
Caracteres Sexuais
Testosterona/análogos & derivados
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glucuronates); 0 (Steroids); 3JEB53B3WT (Algestone); 3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol); KF38W1A85U (11-ketotestosterone); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:9701
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960701
[St] Status:MEDLINE


  9 / 64 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7843561
[Au] Autor:Abdullah MA; Kime DE
[Ad] Endereço:Department of Animal and Plant Sciences, University of Sheffield, United Kingdom.
[Ti] Título:Increased substrate concentration causes a shift from production of 11-oxygenated androgens to 17,20-dihydroxyprogestogens during the in vitro metabolism of 17-hydroxyprogesterone by goldfish testes.
[So] Source:Gen Comp Endocrinol;96(1):129-39, 1994 Oct.
[Is] ISSN:0016-6480
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Goldfish testes were incubated with [3H]17-hydroxyprogesterone in the presence of 0 to 100 micrograms/ml of unlabeled substrate and metabolites examined by thin-layer and high performance liquid chromatography. Conjugated steroids, predominantly sulfates, accounted for 50% of recovered activity with radiolabeled substrate alone, but percentage yields decreased to very low levels with substrate concentrations of 1 micrograms/ml and above. The 11-oxygenated androgens, androstenetrione and 11-ketotestosterone, were the major products with 0 to 0.1 micrograms/ml substrate, but at concentrations of 1 to 100 micrograms/ml the major products were 17,20 alpha-dihydroxy-4-pregnen-3-one (30% of recovered activity) with smaller amounts of the 20 beta-epimer. 11-Deoxycortisol was a minor product at all substrate concentrations. Production of 11-oxygenated androgens in the medium reached a maximum value of 40 ng/100 mg tissue/3 hr with 2 micrograms substrate, but progestogen production continued to increase up to the maximum substrate used (30 micrograms at 200 micrograms substrate). The results demonstrate a clear switch from production of 11-oxygenated androgens to that of 20-reduced progestogens with increased substrate concentration. This switch shows similarities to that observed for in vivo plasma steroid concentrations during the prespawning period of many male teleosts and it is suggested that this, at least in part, may be due to increased substrate availability resulting from elevated gonadotropin secretion.
[Mh] Termos MeSH primário: Algestona/metabolismo
Androgênios/biossíntese
Carpa Dourada/metabolismo
Hidroxiprogesteronas/metabolismo
Testículo/metabolismo
[Mh] Termos MeSH secundário: 17-Hidroxiesteroide Desidrogenases/metabolismo
17-alfa-Hidroxiprogesterona
20-alfa-Di-Hidroprogesterona/metabolismo
Androstenos/metabolismo
Animais
Masculino
Testosterona/análogos & derivados
Testosterona/biossíntese
Trítio
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Androstenes); 0 (Hydroxyprogesterones); 10028-17-8 (Tritium); 145-14-2 (20-alpha-Dihydroprogesterone); 15114-79-1 (20 beta-dihydroprogesterone); 3JEB53B3WT (Algestone); 3XMK78S47O (Testosterone); 68-96-2 (17-alpha-Hydroxyprogesterone); EC 1.1.- (17-Hydroxysteroid Dehydrogenases); KF38W1A85U (11-ketotestosterone)
[Em] Mês de entrada:9503
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:941001
[St] Status:MEDLINE


  10 / 64 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:8224001
[Au] Autor:Gocze PM; Freeman DA
[Ad] Endereço:Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City.
[Ti] Título:Plasma membrane cholesterol is utilized as steroidogenic substrate in Y-1 mouse adrenal tumor cells and normal sheep adrenal cells.
[So] Source:Exp Cell Res;209(1):21-5, 1993 Nov.
[Is] ISSN:0014-4827
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Previous studies from this laboratory indicate that plasma membrane cholesterol acts as an important source of steroidogenic substrate for MA-10 Leydig tumor cells. The present studies were designed to generalize these findings to other steroidogenic cells and to another species. Studies were performed using the Y-1 murine adrenal tumor cell line and primary cultures of sheep adrenocortical cells. Treating Y-1 cells with the acyl coenzyme A:cholesterol acyltransferase inhibitor, 58-035, caused cellular cholesteryl ester depletion and rendered more apparent the effect of dibutyryl-cAMP to cause cellular free cholesterol depletion. Radioactive 20 alpha-dihydroprogesterone was synthesized by Y-1 cells that had been plasma membrane-labeled with [3H]-cholesterol. Primary sheep adrenal cultures that had been cholesteryl ester-depleted also demonstrated cellular free cholesterol depletion after stimulation with dibutyryl cAMP. Plasma membrane label was converted to steroid hormones in these cells as well. Taken together, these data indicate that the use of plasma cholesterol is not restricted to the MA-10 cells. The present data indicate that both neoplastic mouse adrenal tumor cells and normal sheep adrenal cells utilize plasma membrane cholesterol.
[Mh] Termos MeSH primário: Neoplasias das Glândulas Suprarrenais/metabolismo
Glândulas Suprarrenais/metabolismo
Algestona/metabolismo
Membrana Celular/metabolismo
Colesterol/metabolismo
[Mh] Termos MeSH secundário: Glândulas Suprarrenais/citologia
Animais
Bucladesina/farmacologia
Células Cultivadas
Camundongos
Pregnenolona/biossíntese
Ovinos
Esterol O-Aciltransferase/antagonistas & inibidores
Fatores de Tempo
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
3JEB53B3WT (Algestone); 63X7MBT2LQ (Bucladesine); 73R90F7MQ8 (Pregnenolone); 97C5T2UQ7J (Cholesterol); EC 2.3.1.26 (Sterol O-Acyltransferase)
[Em] Mês de entrada:9311
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:931101
[St] Status:MEDLINE



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde